Biolife Solutions Inc. logo

Biolife Solutions Inc. (BJX1)

Market Open
8 Dec, 13:09
XBER XBER
22. 00
0
0%
1.2B Market Cap
- P/E Ratio
0% Div Yield
0 Volume
-1.02 Eps
22
Previous Close
Day Range
21.8 22
Year Range
17.4 28.2
Want to track BJX1 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 84 days

Summary

BJX1 trading today higher at €22, an increase of 0% from yesterday's close, completing a monthly decrease of -2.65% or €0.6. Over the past 12 months, BJX1 stock lost -12%.
BJX1 is not paying dividends to its shareholders.
The last earnings report, released on Nov 06, 2025, exceeded the consensus estimates by 0.05%. On average, the company has fell short of earnings expectations by -0.06%, based on the last three reports. The next scheduled earnings report is due on Mar 02, 2026.
Biolife Solutions Inc. has completed 1 stock splits, with the recent split occurring on Jan 29, 2014.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

BJX1 Chart

Similar

0N5
XOMETRY INC.CL.A -,000001
-
-
OE6
Ibotta Inc.
-
-
G91
Getech Group PLC
0.7
-0.57%
TechTarget, Inc.
-
-
BioLife Solutions, Inc. (BLFS) Q3 2025 Earnings Call Transcript

BioLife Solutions, Inc. (BLFS) Q3 2025 Earnings Call Transcript

BioLife Solutions, Inc. ( BLFS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Troy Wichterman - Chief Financial Officer Roderick de Greef - CEO & Chairman Conference Call Participants Paul Knight - KeyBanc Capital Markets Inc., Research Division Matthew Stanton - Jefferies LLC, Research Division Steven Etoch - Stephens Inc., Research Division Brendan Smith - TD Cowen, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2025 Shareholder and Analyst Conference Call.

Seekingalpha | 1 month ago
BioLife Solutions, Inc. (BLFS) Surpasses Q3 Earnings and Revenue Estimates

BioLife Solutions, Inc. (BLFS) Surpasses Q3 Earnings and Revenue Estimates

BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.02 per share a year ago.

Zacks | 1 month ago
BioLife: Back To Basics Is Getting Traction (Rating Upgrade)

BioLife: Back To Basics Is Getting Traction (Rating Upgrade)

After multiple acquisitions and significant dilution of shareholders, BioLife shed two freezer businesses which it couldn't get going. Focusing mostly on its core biopreservation media business is putting BLFS on much sounder footing, as it generates the highest margins and the company has a competitive advantage. This is already paying off with cash flow steadily increasing.

Seekingalpha | 2 months ago

Biolife Solutions Inc. (BJX1) FAQ

What is the stock price today?

The current price is €22.00.

On which exchange is it traded?

Biolife Solutions Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is BJX1.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 1.2B.

When is the next earnings date?

The next earnings report will release on Mar 02, 2026.

Has Biolife Solutions Inc. ever had a stock split?

Biolife Solutions Inc. had 1 splits and the recent split was on Jan 29, 2014.

Biolife Solutions Inc. Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
Roderick de Greef CEO
XBER Exchange
US09062W2044 ISIN
US Country
159 Employees
- Last Dividend
29 Jan 2014 Last Split
22 Nov 1989 IPO Date

Overview

BioLife Solutions, Inc. is a pivotal entity within the cell and gene therapy (CGT) sector, offering a comprehensive suite of bioproduction tools and services. Established in 1987 and based in Bothell, Washington, this company caters to a global market, including the United States, Europe, the Middle East, and Africa. BioLife Solutions plays a critical role in both the research and commercial manufacturing of biologic-based therapies, addressing the needs of the rapidly evolving CGT industry by developing, manufacturing, and marketing a wide range of products designed to enhance the preservation, growth, and viability of cellular materials.

Products and Services

The offerings of BioLife Solutions are diversified and tailored to meet the specific requirements of the CGT domain. These include:

  • HypoThermosol FRS and CryoStor Freeze Media:

    These proprietary biopreservation media products are engineered to reduce preservation-induced, delayed-onset cell damage and death, thereby enhancing the viability and functional integrity of cellular and gene therapies during the freezing, storage, and transportation processes.

  • Human Platelet Lysates for Cell Expansion:

    An essential tool for the cell therapy sector, these lysates facilitate the expansion and growth of therapeutic cells, providing a superior alternative to traditional fetal bovine serum.

  • CellSeal Closed System Vials:

    Designed for the CGT market, these vials offer a secure method for the containment and transport of cellular products, ensuring product integrity and regulatory compliance.

  • ThawSTAR Automated Thawing Devices:

    This family of devices is specifically developed for thawing frozen cell and gene therapies packaged in cryovials and cryobags, offering standardized, rapid, and reproducible thawing to ensure maximum viability of thawed materials.

  • Cryogenic Freezer Technology:

    Includes controlled rate freezing and cryogenic storage solutions for biologic materials, ensuring long-term preservation of cellular and biomolecular integrity at ultra-low temperatures.

  • Ultra-Low Temperature Mechanical Freezers:

    These freezers provide dependable, energy-efficient storage options for sensitive biological materials and pharmaceuticals, maintaining optimal conditions for long-term viability.

  • Evo Shipping Containers:

    Cloud-connected passive storage and transport containers designed for temperature-sensitive biologics and pharmaceuticals, offering real-time monitoring to ensure product integrity during transit.

  • Liquid Nitrogen Laboratory Freezers, Cryogenic Equipment, and Accessories:

    A comprehensive range of products for the storage and handling of cryogenically preserved biological samples, offering solutions for every stage of the cryopreservation process.

  • Biological and Pharmaceutical Storage and Transport Services:

    Providing end-to-end logistic solutions for the CGT sector, these services ensure the safe, compliant, and efficient transport and storage of sensitive biological materials and pharmaceuticals.

BioLife Solutions markets and sells its products both directly and through third-party distributors, ensuring widespread availability and support for its comprehensive suite of bioproduction tools and services.

Contact Information

Address: 3303 Monte Villa Parkway
Phone: 425 402 1400